Drug interactions
Encorafenib + Ipratropium-salbutamol
Severity: Moderate
Encorafenib and Ipratropium-salbutamol: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib can prolong the QT interval, and salbutamol may add to this, especially at high doses or with hypokalemia. The effect is usually modest with standard inhaled doses.
What this interaction means in plain words
Encorafenib and Ipratropium-salbutamol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Ipratropium-salbutamol belongs to Respiratory.
Why it happens
Additive QT prolongation, with possible beta-agonist-induced hypokalemia.
What to do
Monitor ECG and electrolytes, especially potassium and magnesium, and correct abnormalities before and during therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Ipratropium-salbutamol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipratropium-salbutamol
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Ipratropium-salbutamol?
MediHelp rates the interaction as moderate. Encorafenib and Ipratropium-salbutamol can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib can prolong the QT interval, and salbutamol may add to this, especially at high doses or with hypokalemia. The effect is usually modest with standard inhaled doses.
How serious is the interaction between Encorafenib and Ipratropium-salbutamol?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes, especially potassium and magnesium, and correct abnormalities before and during therapy.
What other medicines interact with Ipratropium-salbutamol?
MediHelp also lists interactions of Ipratropium-salbutamol with, for example, Amisulpride, Arsenic trioxide, Carvedilol. The full list is on the Ipratropium-salbutamol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
